Media & Technology
Impossible Aerospace Corporation (IA); the Rise of Alpine 4 Technologies Ltd (OTCMKTS: ALPP)
Alpine 4 Technologies Ltd (OTCMKTS: ALPP) has made a powerful move up in recent months emerging as a volume leader in small caps. For months the stock sat at its $0.04 base finally taking off in mid-November after the Company announced the acquisition of United States Air Force contractor, Impossible Aerospace Corporation (IA). As part of the acquisition 3 major institutional investors became shareholders in Alpine 4; Airbus Vetnures (one of the largest aviation companies in the world), Bessemer VC (the oldest Venture Capital firm in America) and Eclipse VC.
Alpine 4 is doing big numbers recently reporting $8,729,633 in revenues for the 3 months ended, September 30, 2020 up from $7 million for the same period last year. Microcapdaily reported on ALPP on November 17 when the stock was around $0.07 pointing out the Company and its subsidiaries keep inking multi-million dollar contracts many of them in the coronavirus space. The Company’s subsidiary Morris Sheet Metal Corp recently reported it secured several new health care building projects for its hospital clientele to build isolation rooms.
Alpine 4 Technologies Ltd (OTCMKTS: ALPP) is a publicly traded enterprise with business related endeavors in, Software, Automotive Technologies, Electronics Manufacturing, and Energy Services & Fabrication Technologies. However Alpine 4’s acquisition model is industry agnostic and is based around our Driver, Stabilizer, Facilitator business model. Four principles at the core of the Company’s business are: Synergy. Innovation. Drive. Excellence. Alpine 4 currently owns 11 operating subsidiaries: Altia llc; Quality Circuit Assembly, Inc., American Precision Fabricators, Inc., Morris Sheet Metal, Corp, JTD Spiral, Inc., Deluxe Sheet Metal, Inc, and Excel Fabrication, LLC. In the first quarter of 2020, Alpine 4 created three additional subsidiaries to act as silo holding companies, organized by industries. These silo subsidiaries are A4 Construction Services, Inc. A4 Manufacturing, Inc. and A4 Technologies, Inc. All three are Delaware corporations.
The Company is currently acquiring Impossible Aerospace Corporation. Impossible Aerospace builds high-performance electric aircraft and drones. Its customers range from the US Airforce to the City of Santa Clara, and other municipalities. Impossible Aerospace is Alpine 4’s first acquisition in the UAV space and will serve as a cornerstone to build upon. Upon completion of the transaction Impossible Aerospace will be a wholly owned subsidiary of Alpine 4. The three major institutional investors that are now Shareholders in Alpine 4 are Airbus (one of the largest aviation companies in the world), Bessemer VC (the oldest Venture Capital firm in America) and Eclipse VC.
Microcapdaily reported on ALPP in November when the stock was around $0.07 pointing out the Company and its subsidiaries keep inking multi-million dollar contracts many of them in the coronavirus space. The Company’s subsidiary Morris Sheet Metal Corp reported it secured several new health care building projects for its hospital clientele to build isolation rooms. Alpine 4 is doing big numbers recently reporting $8,729,633 in revenues for the 3 months ended, September 30, 2020 up from $7 million for the same period last year.
Alpine 4 has been busy beefing up its management team appointing Spencer Gore to the team as a corporate strategy consultant. Mr. Gore was brought on with three primary goals. The first was to help in the transfer of IP associated with the sale of Impossible Aerospace to Alpine 4. The second was to help Alpine 4 capitalize on Mr. Gore’s extensive knowledge of commercial drones and his experience in battery technologies. Finally, the company feels that Mr. Gore’s time spent with Tesla and Space X will help Impossible Aerospace execute on the growing demand from the US Air Force for domestically made electric aircraft.
To Find out the inside Scoop on ALPP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Alpine 4 has appointed Larry Zic as its VP / Corporate Controller. Mr. Zic, a CPA was a Senior Vice President of Finance for Saks, Inc., a $5b annual retail department store chain. He has been part of implementing 12 ERP systems over his career. It is this experience that will help advance the execution of Alpine 4’s SPECTRUMebos ERP system both internally and commercially. The Company also appointed Craig Codling as its Chief Technology Officer. Prior to joining Alpine 4, Craig worked for Ancestry.com as a lead development architect. His team led the way for the creation of several new innovations that allowed Ancestry.com to facilitate billions of transactions daily. Craig was also the founder of Kiware, Inc., a robust ERP platform for the manufacturing and wholesale industries.
On November 23 Alpine 4 announced Impossible Aerospace Corporation (IA) has completed its final deliverable on its first $1.5 million contract with the United States Air Force. The SBIR (Small Business Innovation Research) contract financed the testing, delivery and deployment of several Impossible Aerospace US-1 aircraft into an operational defense environment. While several American companies have announced or launched American-built small unmanned aircraft systems (sUAS), the unique endurance, robustness and sensing capabilities of US-1 have been put to work protecting the nation’s critical defense systems, including its stockpile of nuclear ICBMS across the western United States.
On December 2 Alpine 4 reported its subsidiary, Excel Fabrication LLC., is now an approved Varco Pruden Buildings supplier of steel structures for commercial building. Excel has provided construction services to the western United States for 12 years. The company is excited to provide steel construction and metal building systems as an economical and aesthetically pleasing design option. Excel has joined Varco Pruden’s builder network in an effort to offer more options to their customers. The company expects that being a part of the Varco Pruden Builder network will give Excel’s customers greater access to pre-engineered and conventional steel solutions, use of the company’s advanced engineering program and contact with architects and engineers. It is for this reason that Alpine 4 is expanding its reach of General Contracting starting with the following 7 states: Montana, Oregon, Washington, Idaho, Utah, Nevada and Wyoming.
Kent Wilson, CEO of Alpine 4, had this to say, “I must emphasis how big of a deal this is for Excel and A4 Constructions Services, Inc., and we are very pleased to partner with Varco Pruden Buildings as our sole source of steel building offerings. It’s important to point out that over the past month, as we have begun to incorporate Varco Pruden Buildings into our bidding process, our job bidding has swelled to over $100 million. This is a 500% increase over our job bidding prior to being in their network. This is solely related to the strong name recognition and branding of Varco Pruden Buildings.”
$ALPP Enters the Commercial Drone Market With its Acquisition of Impossible Aerospace Corporation
https://t.co/dcRQMcSwLy— Alpine 4 Holdings, Inc. (@alpine4holdings) November 17, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Alpine 4 has made a powerful move up in recent months emerging as a volume leader in small caps. For months the stock sat at its $0.04 base finally taking off in mid-November after the Company announced the acquisition of United States Air Force contractor, Impossible Aerospace Corporation (IA). As part of the acquisition 3 major institutional investors became shareholders in Alpine 4; Airbus Ventures (one of the largest aviation companies in the world), Bessemer VC (the oldest Venture Capital firm in America) and Eclipse VC. Alpine 4 is doing big numbers recently reporting $8,729,633 in revenues for the 3 months ended, September 30, 2020 up from $7 million for the same period last year. Microcapdaily reported on ALPP on November 17 when the stock was around $0.07 pointing out the Company and its subsidiaries keep inking multi-million dollar contracts many of them in the coronavirus space. The Company’s subsidiary Morris Sheet Metal Corp recently reported it secured several new health care building projects for its hospital clientele to build isolation rooms. We will be updating on ALPP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ALPP.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ALPP either long or short and we have not been compensated for this article.
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX.
All I did was follow the system.
It has a small float.
Fresh meet never pumped before.
Big News out.
Giant volume.
Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz— Trader Brian Jones (@MasterBJones) June 2, 2023
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.Â
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
— Jake Weber (@BioStockAnalyst) June 2, 2023
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
— Jake Weber (@BioStockAnalyst) June 2, 2023
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.
Revolutionizing User Experience and Driving Stock Surge
$onfo in news and float are lit pic.twitter.com/7afKMOfdz2
— …frankyboyz… (@frankyboyz77) May 26, 2023
With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.
To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ONFO just took the elevator to the top!
Now just waiting on $CYTO pic.twitter.com/OfJgNb1ty0
— 💎 DBR 💎 (@dbr_land) May 26, 2023
Evaluating Financial Performance
While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.
*says the word "AI" once
* $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2
— Commonstock (@JoinCommonstock) May 26, 2023
Investment Outlook and Future Prospects
Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.
$onfo in news and float are lit pic.twitter.com/Q8eIveRfgd
— …frankyboyz… (@frankyboyz77) May 26, 2023
About MightyDeals.com
Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.
About Onfolio Holdings Inc.
Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.
$ONFO #Ai have you seen this stock? Just came out with a competitive AI software that will fight against the tech kings #microsoft #google
— Don’t Look Down (@M_1Ball) May 26, 2023
Conclusion
Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.
$ONFO – "AI program" is laughable. Check it out on https://t.co/0LdCQCWC28. I searched for "shoes" and flower bouquets showed up. I put in a search for "dogs" and african animals came up.
Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr
— Adam Gefvert, CFA (@Shiningboy) May 26, 2023
We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership
Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
